Industry leaders at CPHI Europe emphasize sound science in navigating regulatory challenges for pharmaceutical excipients and ingredients.

Lifecore Biomedical has been chosen to execute a commercial site transfer and become the primary manufacturing supplier for a major injectable pharmaceutical product, further strengthening its position as a leading U.S.-based contract development and manufacturing organization.

Cambridge Isotope Laboratories launches a unified ISOAPI-D brand of deuterated reagents for API synthesis, enhancing pharmaceutical supply chains and manufacturing quality, at CPhI Frankfurt 2025.

Catalent has announced a significant corporate transformation aimed at overhauling its manufacturing operations after a year of major industry shifts.

Alphamab Oncology secures regulatory approval to commence a pivotal Phase III clinical study of the innovative HER2-targeting ADC JSKN003 for advanced colorectal cancer in China, marking a major milestone in Asia's oncology drug development landscape.

Innovent Biologics and Takeda Pharmaceutical have announced a transformative $11.4 billion global oncology partnership for the development and commercialization of advanced cancer therapies.

Abolis Biotechnologies and EUROAPI launch a major partnership under the IPCEI Med4Cure program to restore EU production of corticosteroids and secure critical supply chains.

Chinese biotech Biokin receives a $250 million milestone payment from BMS, marking the largest ADC deal to date, and drives accelerated global regulatory progress for its innovative cancer drug.

INEOS warns that European pharmaceutical supply chains and manufacturing capacity are imperiled by high energy costs, carbon taxes, and lack of regulatory support, calling for urgent EU intervention.

The FDA has restricted updated COVID-19 vaccine approvals to seniors and certain high-risk individuals under 65, ending routine access for healthy children and pregnant women and raising operational, regulatory, and supply chain concerns across the pharma sector.